Chordate Medical Holding
7,28
SEK
-5,45 %
Mindre end 1K følgere
CMH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-5,45%
+13,4%
-34,71%
-7,7%
-54,08%
-67,62%
-96,75%
-95,92%
-99,57%
Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulatory and drug-free treatment technique for chronic migraine and chronic rhinitis. The treatment has proven efficacy according to a clinical study and is marketed in selected markets in the EU and the Middle East. The company is headquartered in Kista.
Læs mereMarkedsværdi
19,65 mio. SEK
Aktieomsætning
28,33 t SEK
Omsætning
660 t
EBIT %
-4.159,09 %
P/E
-
Udbytteafkast, %
-
Finanskalender
29.8
2025
Delårsrapport Q2'25
21.11
2025
Delårsrapport Q3'25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Chordate Medical Holding AB (publ) Interim Report January-March 2025
Communiqué from the Annual General Meeting of Chordate Medical Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools